Cytosorbents Corporation
CTSO
$0.8923
-$0.0208-2.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.76% | -2.92% | 91.64% | 6.58% | -6.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.76% | -2.92% | 91.64% | 6.58% | -6.14% |
| Cost of Revenue | 19.84% | 19.08% | 83.12% | 28.24% | -31.25% |
| Gross Profit | 4.78% | -9.69% | 38.97% | -5.80% | 8.05% |
| SG&A Expenses | 7.17% | -9.17% | -14.25% | -13.99% | -3.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.61% | -7.56% | -22.05% | -14.12% | -22.23% |
| Operating Income | -1.26% | 16.52% | 58.71% | 39.56% | 45.40% |
| Income Before Tax | 145.34% | 75.72% | -29.60% | 74.61% | 30.21% |
| Income Tax Expenses | -- | -- | -107.79% | -- | -- |
| Earnings from Continuing Operations | 145.34% | 75.72% | -19.92% | 74.61% | 30.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 145.34% | 75.72% | -19.92% | 74.61% | 30.21% |
| EBIT | -1.26% | 16.52% | 58.71% | 39.56% | 45.40% |
| EBITDA | -1.30% | 17.38% | 60.95% | 41.58% | 48.35% |
| EPS Basic | 139.32% | 78.28% | -2.05% | 79.30% | 43.42% |
| Normalized Basic EPS | 139.27% | 78.25% | -7.01% | 79.43% | 43.28% |
| EPS Diluted | 137.50% | 78.28% | -2.05% | 79.30% | 42.78% |
| Normalized Diluted EPS | 136.64% | 78.25% | -7.01% | 79.43% | 43.28% |
| Average Basic Shares Outstanding | 15.29% | 11.57% | 17.53% | 22.71% | 23.38% |
| Average Diluted Shares Outstanding | 23.68% | 11.57% | 17.53% | 22.71% | 23.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |